• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2020 Fiscal Year Final Research Report

Elucidation of mechanisms for novel CF6-relating anti-aging protein NM_026333 and application for drug discovery

Research Project

  • PDF
Project/Area Number 18K08023
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 53020:Cardiology-related
Research InstitutionHirosaki University

Principal Investigator

OSANAI TOMOHIRO  弘前大学, 保健学研究科, 教授 (00169278)

Project Period (FY) 2018-04-01 – 2021-03-31
Keywordsanti-aging / NM_026333 / coupling factor 6 / acidosis / channel / NCX1 / NCLX
Outline of Final Research Achievements

Based on the background that coupling factor 6 (CF6) accelerates acidosis-mediated aging though a causative gene NM_026333, we searched the target molecules and inhibitors of protein relevant to NM_026333. We found NCX1 (Na+-Ca2+ exchanger) as a target of NM_026333, and SN-6 is a selective inhibitor of NCX1. SN-6 rescued CF6-transgenic mouse-derived cells (TG cells) from multiple aging hallmarks, including epigenetic alteration, impaired autophagy, and nuclear membrane-related genomic instability, and elongated telomere length in the TG cells. We confirmed that telomere length of leukocytes was shorter in the TG mice at the age of 100 weeks compared with age-matched control mice, but was extended by 15% by intraperitoneal injection of CNAP (NM_026333 recombinant protein) or SN-6. Human gene that is relevant to mouse NM_026333 was undetected.

Free Research Field

医歯薬学

Academic Significance and Societal Importance of the Research Achievements

老化抑制効果を有する新規NM_026333の結合蛋白がNCX1と同定され、その有用性が確認されたことは、創薬を考えた上で極めて重要である。これらの研究は、細胞内酸性化による老化促進機序にCF6がどのように関与するかを明らかにできた点で学術的な意義がある。NM_026333の結合蛋白はチャネル蛋白質であり、チャネルの阻害薬がCF6による細胞老化のみならず個体老化をも抑制した。CF6は老化を促進させ創薬に向けた分子標的となる可能性が大である。本研究の社会的意義は、老化の新しい機序の解明並びにCF6阻害剤の開発が開始され、健康寿命等の将来の医療に還元・貢献できることが期待されることである。

URL: 

Published: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi